Year Founded
2023
Ownership
Private
Employees
~50
Therapeutic Areas
Rare Diseases
Stage
Phase 2
Modalities
Small molecule

Tisento Therapeutics General Information

Phase 2a clinical data showed rapid improvements in disease-associated biomarkers in MELAS patients, with excellent safety profile, CNS exposure, and improvements in neuronal function, mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. Currently enrolling Phase 2b PRIZM study.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States

Drug Pipeline

zagociguat
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Tisento Therapeutics's pipeline data

Book a demo

Key Partnerships

Cyclerion Therapeutics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Tisento Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Tisento Therapeutics's complete valuation and funding history, request access »

Tisento Therapeutics Investors

Polaris Partners (Private Equity Owner)[3]
Investor Type: Venture Capital
Holding: Minority
Sanofi Ventures
Investor Type: Venture Capital
Holding: Minority
Venrock
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »